Tranexamic Acid

Drug Levels and Effects:




Summary of Use during Lactation:


No information is available on the clinical use oftranexamicacidduring breastfeeding. However, because amounts in breastmilk appear to be low and the drug has a half-life of about 2 hours, waiting for 3 to 4 hours after a dose before nursing again should minimize the infant dosage. However, an international consensus panel recommends against usingtranexamicacidduring breastfeeding.[1]


Drug Levels:


Maternal Levels.

Unpublished data from the manufacturer indicates that the concentration oftranexamicacidin breastmilk is 1% of the peak serum concentration 1 hour after the last dose of a 2-day treatment course.[2] Further details of the study have not been published.

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


Relevant published information was not found as of the revision date.


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


References:


1. Caballero T, Farkas H, Bouillet et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol. 2011 PMID:22197274
2. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs. 1985;29:236-61. PMID:2580684



Substance Identification:




Substance Name:

TranexamicAcid

CAS Registry Number:

1197-18-8

Drug Class:


  • Antifibrinolytic Agents


  • Administrative Information:




    LactMed Record Number:


    828


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.